| Identification | Back Directory | [Name]
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine | [CAS]
21062-28-2 | [Synonyms]
SKOG102
WR-81844
1-(3,4-Dichlorophenyl)-3-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-2-pyrimidinyl]guanidine
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine
Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[(1-ethyl-3-piperidinyl)amino]-6-methyl-2-pyrimidinyl]- | [Molecular Formula]
C19H25Cl2N7 | [MDL Number]
MFCD01724203 | [MOL File]
21062-28-2.mol | [Molecular Weight]
422.35 |
| Chemical Properties | Back Directory | [Boiling point ]
573.54°C (rough estimate) | [density ]
1.1768 (rough estimate) | [refractive index ]
1.6300 (estimate) | [pka]
8.80±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
SKOG102 is a potent OLIG2 inhibitor that is directly engaging OLIG2 and interferes with the ability of OLIG2 to bind DNA. SKOG102 can be used for the research of glioblastoma (GBM)[1]. | [in vivo]
SKOG102 (10-20 mg/kg; i.p.) inhibits GBM4 tumor growth in mice[1].
SKOG102 (5 mg/kg; i.p.) accumulates in the tumor even over a relatively brief time period and the plasma and brain concentrations are almost identical at 4 hours after injection in mice[1]. | Animal Model: | NSG mice were inoculated in each flank with GBM4 cells[1] | | Dosage: | 10, 15, and 20 mg/kg; dissolved in solutol:PEG400:water (20%:40%:40%) | | Administration: | Intraperitoneal injection; first 2 weeks (from day 33 to 46) 10 mg/kg, third week (from day 47 to 54) 15 mg/kg, fourth week (from 55 to 66) first 3 days 20 mg/kg, 2 days break, then alternate days from day 60 to 66 | | Result: | Significantly attenuated tumor growth.
|
| [References]
[1] Tsigelny IF, et, al. Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma. Oncotarget. 2017 Apr 4;8(14):22370-22384. DOI:10.18632/oncotarget.5633 |
|
|